Skip to main content
|
  1. Home
  2. Clinical Trials
  3. MK1022-011 (Cohort 3)

Safety and Efficacy of Patritumab Deruxtecan in Gastrointestinal Cancers

Short Title: MK1022-011 (Cohort 3)


Enrollment Status: Recruiting

NCT #: NCT06596694

Specialty Area: Oncology

Condition Studied: Hepatocellular Carcinoma

Age Groups: Adult; Older Adult

Phase: I/II


Study Information

Summary / Purpose

To evaluate the safety, tolerability, and anti-tumor activity of patritumab deruxtecan in patients with advanced gastrointestinal cancers expressing HER3.

Study Type: Interventional
Accepts Healthy Volunteers: No

Who Can Participate

Eligibility Criteria:
  • Adults 18+ years of age
  • Diagnosed with hepatocellular carcinoma (HCC)
  • Must have HER3 expression
  • Disease progression after 1 standard systemic therapy
  • Adequate organ and marrow function

What's Involved

Participation in the study will include:
  • Intravenous (IV) infusion of patritumab deruxtecan every 3 weeks
  • Continued treatment until disease progression or unacceptable side effects
  • Regular CT or MRI scans to monitor response to treatment
  • Blood tests to check your health and how the treatment is working

Principal Investigator

Additional Information

Location: Renown Health, Office of Clinical Research
Address:

1500 E 2nd St. Reno, NV 89502

General Research: 775-982-3646
Oncology Research: 775-982-5050
Email: Renown-CRD@renown.org

Complete Study Details: https://clinicaltrials.gov/study/NCT06596694

Disclaimer: This listing gives you general information about the study and isn't part of the official consent process. If you decide to learn more, the research team will talk with you and check if you meet any additional requirements to join the study.

ER Wait Times

How are wait times calculated?

Our estimated ER wait times reflect the average time from check-in to being seen by a medical professional during triage, where patients are prioritized based on the severity of their condition.

Health & Wellness eNews
Sign Up